Skip to main content
. 2020 Mar 25;9(4):275. doi: 10.3390/antiox9040275

Figure 1.

Figure 1

Corylin reduces inflammation in tumor necrosis factor-α (TNF-α)-treated human umbilical vein endothelial cells (HUVECs) and vascular smooth muscle cells (VSMCs) by downregulating vascular cell adhesion protein-1 (VCAM-1) expression. (A) Chemical structure of corylin. HUVECs and VSMCs were treated with 0, 5, 10, or 20 ng/mL TNF-α alone for 24 h (B), 0, 5, 10, 20, or 40 µM corylin alone for 24 h, (C) or pretreated (1 h) with 10, 20 or 30 µM corylin and then treated with 10 ng/mL TNF-α for 24 h. (D) SRB assay was performed to observe cell viability. (E,F) Immunofluorescence staining and Western blot analysis were performed to evaluate the level of VCAM-1 protein expression. β-actin was used as an internal control for sample loading. Nuclei were labeled with DAPI (blue). (G) Quantitative real-time PCR was performed to evaluate the VCAM-1 mRNA expression. HUVECs or VSMCs were pretreated (1 h) with 10 or 20 µM corylin (C10 or C20) and then treated with 10 ng/mL TNF-α (T) for 6 h. The data are shown as the mean ± SD. * p < 0.05 versus the untreated group (CTRL). † p < 0.05 versus the TNF-α-treated group. Scale bars = 50 μm (E).